BS_E94QRJDW
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 35.611038107752954
- age_years
- 2.205
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.554
- IL6_JAK_STAT3_SIGNALING+0.519
- TNFA_SIGNALING_VIA_NFKB+0.515
- INTERFERON_GAMMA_RESPONSE+0.509
- ALLOGRAFT_REJECTION+0.502
- INFLAMMATORY_RESPONSE+0.469
- INTERFERON_ALPHA_RESPONSE+0.467
- COMPLEMENT+0.434
- ANDROGEN_RESPONSE+0.416
- KRAS_SIGNALING_UP+0.322
Top 10 suppressed
- E2F_TARGETS-0.393
- G2M_CHECKPOINT-0.376
- DNA_REPAIR-0.248
- MITOTIC_SPINDLE-0.219
- SPERMATOGENESIS-0.136
- OXIDATIVE_PHOSPHORYLATION-0.069
- HEME_METABOLISM-0.050
- PEROXISOME-0.048
- WNT_BETA_CATENIN_SIGNALING-0.046
- BILE_ACID_METABOLISM-0.034
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.924 |
| 2 | BS_X91K8KMG | pilocytic astrocytoma | — | 0.919 |
| 3 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.906 |
| 4 | BS_SXRS2P6T | low-grade glioma | — | 0.900 |
| 5 | BS_EN2VK7NY | low-grade glioma | — | 0.894 |
| 6 | BS_MF9X3PKH | low-grade glioma | — | 0.890 |
| 7 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.886 |
| 8 | BS_N1E0H8YQ | low-grade glioma | — | 0.885 |
| 9 | BS_FAQQ0GCQ | Ganglioglioma | — | 0.884 |
| 10 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.554 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.519 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.515 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.509 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.502 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.469 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.467 | Inavolisib | — uncovered |
| COMPLEMENT | 0.434 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.416 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.322 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.314 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.313 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.301 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.298 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.292 | Remibrutinib | — uncovered |
| COAGULATION | 0.292 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.285 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.277 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.269 | Idelalisib | — uncovered |